Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 116
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Respimat, Tiotropium; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 3,991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 57
States / cities: Birmingham, Alabama • Mobile, Alabama • Berkeley, California + 48 more

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 85
States / cities: Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more

Conditions: Asthma
Interventions: indacaterol maleate; Drug
Lead sponsor: Novartis; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Minneapolis, Minnesota + 2 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK573719, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Sunset, Louisiana • Easley, South Carolina • Spartanburg, South Carolina + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK573719 125mcg, GSK573719 250mcg, GSK573719 500mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Madisonville, Kentucky • Charlotte, North Carolina • Spartanburg, South Carolina + 1 more

Conditions: Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg, Placebo, Placebo/moxifloxacin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder, Placebo Inhalation Powder 1, Placebo Inhalation Powder 2; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 23
States / cities: Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK2269557 ELLIPTA DPI, Placebo ELLIPTA DPI, Activated charcoal; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo matching Olodaterol, Olodaterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 90
States / cities: Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 79 more

Conditions: Asthma
Interventions: tiotropium Respimat low dose, placebo Respimat, tiotropium Respimat high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more

Conditions: Alzheimer's Disease, Cognitive Dysfunction
Interventions: Formoterol A, Formoterol B (placebo); Drug · Other
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions: Aclidinium Bromide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 3,635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 433
States / cities: Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: carmoterol (CHF 4226), salmeterol, placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: Jonesboro, Arkansas • Fresno, California • San Diego, California + 19 more

Conditions: Healthy Volunteers
Interventions: C16TR, Placebo, Tyvaso®; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA inhaler, Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler, Placebo inhalation powder via ACCUHALER/DISKUS inhaler, Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more

Conditions: Asthma
Interventions: BI 1744 CL; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 10
States / cities: Lakewood, California • Los Angeles, California • San Diego, California + 6 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: 62.5/25mcg, 62.5mcg, 25mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 37
States / cities: Tucson, Arizona • Los Angeles, California • Ormond Beach, Florida + 33 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more

Conditions: Asthma
Interventions: Placebo MDPI, Albuterol MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 35
States / cities: Costa Mesa, California • Encinitas, California • Huntington Beach, California + 30 more

Conditions: Seasonal Allergic Rhinitis
Interventions: 80 mcg Ciclesonide, 160 mcg Ciclesonide, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Conditions: Asthma
Interventions: beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 37
States / cities: Huntington Beach, California • Long Beach, California • Mission Viejo, California + 31 more

Search by objective public record fields.

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Tiotropium / Respimat One Year Study in COPD.

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

28-day Repeat Dose Study of GSK573719

Cardiac Safety of Indacaterol

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

Dose Finding Study of CHF 4226 for Treating Patients With COPD

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Evaluation of Two Doses of QVAR by Breath Operated and Metered Dose Inhalers in Asthmatic Children